Citation

Deruiter J, Holston PL, Deruiter TJ. U.S. Pharmacist 2019; 44(10): 18-28.

Copyright

(Copyright © 2019)

DOI

unavailable

PMID

unavailable

Abstract

New molecular entities (NMEs), as defined by the FDA, are new drug products containing as their active ingredient a chemical substance marketed for the first time in the United States. The following descriptions of NMEs approved in 2018-2019 (table 1) details the basic clinical and pharmacologic profiles of each new drug, as well as key precautions and warnings. Also included is a brief summary of selected pharmacokinetic, adverse-reaction, drug-interaction, and dosing data submitted to the FDA in support of the manufacturer's New Drug Application. This review is intended to be objective rather than evaluative in content. The information for each NME was obtained primarily from sources published prior to FDA approval. Experience clearly demonstrates that many aspects of a new drug's therapeutic profile are not detected in premarketing studies and emerge after the drug is used in large numbers of patients. Studies have demonstrated the appearance of "new" adverse reactions for many NMEs within several years after they first become available. Some of these drugs may eventually acquire at least one black box warning for serious adverse drug reactions or are withdrawn from the market for safety reasons that were not recognized at the time of approval. Therefore, while this review offers a starting point for learning about new drugs, it is essential that practitioners be aware of changes in a drug's therapeutic profile as reported in the pharmaceutical literature and by their own patients. © 2019, Jobson Publishing Corporation. All rights reserved.

Language: en

Keywords

United States; human; abdominal pain; suicidal ideation; suicide attempt; suicidal behavior; migraine; fatigue; vomiting; antidepressant agent; drug metabolism; xerostomia; headache; somnolence; urine retention; constipation; drug mechanism; heart infarction; hot flush; nonhuman; drug safety; placebo; cerebrovascular accident; backache; benzodiazepine derivative; opiate derivative; carbamazepine; drug efficacy; beta adrenergic receptor blocking agent; diarrhea; nausea; bronchitis; drug effect; hypertension; side effect; clinical study; hypocalcemia; QT prolongation; arthralgia; gastrointestinal disease; chronic obstructive lung disease; spine fracture; antineoplastic agent; drug approval; drug contraindication; 4 aminobutyric acid; flatulence; multiple sclerosis; abdominal distension; demyelinating disease; bradycardia; bronchospasm; drug dose regimen; dizziness; immunosuppressive agent; diltiazem; verapamil; drug bioavailability; Article; atrioventricular block; new drug; injection site reaction; 4 aminobutyric acid A receptor; continuous infusion; upper respiratory tract infection; rifampicin; immunomodulating agent; bone development; drug excretion; fluconazole; decreased appetite; progressive multifocal leukoencephalopathy; postnatal depression; rhinopharyngitis; recommended drug dose; cytochrome P450 2C9; alemtuzumab; skeleton malformation; maximum plasma concentration; intestine motility; osteolysis; pharmacokinetics; live vaccine; peristalsis; fetus disease; hypertransaminasemia; prucalopride; postmenopause osteoporosis; Food and Drug Administration; ossification; oropharynx pain; volume of distribution; severe renal impairment; end stage renal disease; pollakisuria; posterior reversible encephalopathy syndrome; elimination half-life; brexanolone; altered state of consciousness; chronic cough; chronic idiopathic constipation; cyclosporine; cytochrome P450 2C9 inhibitor; macular edema; open angle glaucoma; plasma clearance; revefenacin; romosozumab; siponimod